This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Biotech Stock Mailbag: Cytori Therapeutics

My beef with Cytori is that the company seems disinterested in running real clinical studies. Instead, the company supports pseudo-studies that produce marketing pitches instead of scientific data. This strategy isn't helping Cytori, either. The company struggles to sell the Celution Systems device in Europe and Japan (witness the disappointing results from the first quarter) and doesn't appear to be making any headway with reimbursement. Cytori's efforts at gaining any regulatory approval at all in the U.S. also have been stymied.

I asked Cytori to explain why the company does not support controlled studies of stem cell-enriched fat, including the physician-sponsored study mentioned above.

"Generally speaking, when no generally accepted therapy exists, showing improvement in single arm prospective trials is the next best alternative to a controlled trial," said Cytori spokesperson Megan McCormick.

She added, "In this case, the medical literature supports the fact that there is no standard of care for lumpectomy reconstruction. That is perhaps why this physician chose not to incorporate a control arm. Additionally, ethical, statistical and logistical issues effectively prohibit comparative studies planned to test two experimental treatments against each other."

My response to McCormick (admittedly somewhat snide but still on point) was that perhaps the U.K. physician chose not to use a control arm in his study because his hospital purchased an expensive Celution System device and needs to recoup the investment. The doctor might be afraid that if he performed a regular and relatively inexpensive fat graft, he'd find the outcome to be the same as one using the more expensive Cytori "enhanced" stem cell-fat graft.

On a more serious note, Cytori's assertion that a controlled study would be ethically or logistically impossible is not shared by leading plastic surgeons. I covered this ground last May in an interview with Dr. Karol Gutowski, a plastic surgeon affiliated with the University of Chicago and chairman of a 2009 task force of the American Society of Plastic Surgeons that examined the safety and efficacy of fat grafting procedures.

"The patient satisfaction data [from Restore 2] are meaningless without a comparison to an alternative (or no) therapy. It's like asking a kid, how much do you like ice cream? Compared to what?" said Gutowski last May. [Restore 2 is another breast reconstruction study using stem cell-enriched fat grafts that was conducted by Cytori.]

Stock quotes in this article: CYTX, BPAX, VRTX, MRK, YMI, INCY 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs